"James Doucet-Battle has given us a brilliant book that uncovers the networks that support the pharmacapitalism of Type 2 diabetes. In this important study, we see the impact of economizing risk through biomarketing. Sweetness in the Blood is a must-read because it underscores the sacrificial labor of Black people as they become the targets of risk assessments for Type 2 diabetes and role that the technology plays in constructing ‘racial risk.’"—Dána-Ain Davis, author of Reproductive Injustice: Racism, Pregnancy, and Premature Birth
"Sweetness in the Blood is an indictment, not only of the global sugar industry, but of medical and biotech industries that insist on using biological race as a lens to explain and predict health disparities. Traversing breathtaking terrain, from sugar plantations to pharmaceutical board rooms, this is a must-read for everyone who wants to understand how social inequity gets under the skin and for all those committed to health justice."—Ruha Benjamin, author of Race After Technology
"Sweetness in the Blood adds nuance to our understanding of race and chronic disease prevention management."—Ethnic and Racial Studies
"In Sweetness in the Blood: Race, Risk, and Type 2 Diabetes, James Doucet-Battle offers a sweeping indictment of ways in which racial essentialism infiltrates the science and industry surrounding modern diabetes."—Social Forces
"In this important contribution to deconstructing the intersections of race, capital, and disease, Doucet-Battle employs an ethnographic approach to explore the racialization of a disease, showing how the combined enterprises of pharma and medicine have constructed being African American as a risk. "—CHOICE
"Doucet-Battle successfully presses his readers to question a handful of taken-for-granted concepts (i.e., race, risk, and diabetes). In that respect, Sweetness in the Blood is a wonderful example of the sociological craft. "—American Journal of Sociology
